GLIKNIK LICENSEE PFIZER RECEIVES ORPHAN DRUG DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR DRUG CANDIDATE DIRECTED TOWARDS RARE NEUROLOGICAL DISORDER

Gliknik announced last month that its licensee Pfizer has received orphan drug designation from the US Food and Drug Administration (FDA) for its autoimmune candidate drug GL-2045 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder. CIDP is characterized by progressive weakness and impaired sensory function in the legs and arms.